Royalty Pharma RPRX Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:NotesReceivableGross.
The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Royalty Pharma's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Royalty Pharma's accounts receivable?
- Royalty Pharma (RPRX) reported accounts receivable of $20.04B in Q1 2026.
- How has Royalty Pharma's accounts receivable changed year-over-year?
- Royalty Pharma's accounts receivable increased by 3.3% year-over-year, from $19.41B to $20.04B.
- What is the long-term trend for Royalty Pharma's accounts receivable?
- Over 5 years (2020 to 2025), Royalty Pharma's accounts receivable has grown at a 103.4% compound annual growth rate (CAGR), from $587.19M to $20.46B.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.